dc.contributor.author |
Benekli, M |
|
dc.contributor.author |
Yalcin, S |
|
dc.contributor.author |
Ozkan, M |
|
dc.contributor.author |
Elkiran, ET |
|
dc.contributor.author |
Sevinc, A |
|
dc.contributor.author |
Cabuk, D |
|
dc.contributor.author |
Coskun, HS |
|
dc.contributor.author |
Oksuzoglu, B |
|
dc.contributor.author |
Bayar, B |
|
dc.contributor.author |
Akbulat, A |
|
dc.contributor.author |
Ozet, A |
|
dc.date.accessioned |
2022-10-13T11:46:38Z |
|
dc.date.available |
2022-10-13T11:46:38Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/79596 |
|
dc.description.abstract |
Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. |
|
dc.description.abstract |
Patients and methods: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib. |
|
dc.description.abstract |
Results: Thirty patients with complete data were analyzed: 14 DTC (papillary number [n] = 10; follicular n=4) and 16 MTC. The median age of the patients was 57 years (range: 28-79 years), and there were 18 males and 12 females. All DTC patients were iodine refractory and had received a median three doses of radioactive iodine (range: 1-7 doses). Sorafenib was used for a median of 12 months (range: 1-49 months). The overall response rate was 20%, all partial responses, with no complete response. The overall response rate was 14% in DTC and 25% in MTC patients. The median progression-free survival (PFS) was 17.1 months (95% confidence interval [CI]: 7.3-26.8) and overall survival (OS) was not reached. The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8-36.7) versus 14.5 months (95% CI: 3.7-25.2), respectively (P=0.36), with the median OS not reached in either group (P=0.17). Tumor marker levels did not have any prognostic or predictive role. The toxicity profile was similar to that of other sorafenib trials. |
|
dc.description.abstract |
Conclusion: Sorafenib is an effective and well-tolerated treatment in advanced thyroid cancers. |
|
dc.description.abstract |
C1 [Benekli, Mustafa; Ozet, Ahmet] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey. |
|
dc.description.abstract |
[Yalcin, Suayib] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06100 Ankara, Turkey. |
|
dc.description.abstract |
[Ozkan, Metin] Erciyes Univ, Fac Med, Dept Med Oncol, Kayseri, Turkey. |
|
dc.description.abstract |
[Elkiran, Emin Tamer] Inonu Univ, Fac Med, Dept Med Oncol, Malatya, Turkey. |
|
dc.description.abstract |
[Sevinc, Alper] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey. |
|
dc.description.abstract |
[Cabuk, Devrim] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey. |
|
dc.description.abstract |
[Coskun, Hasan Senol] Akdeniz Univ, Fac Med, Dept Med Oncol, TR-07058 Antalya, Turkey. |
|
dc.description.abstract |
[Oksuzoglu, Berna] Ankara Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. |
|
dc.description.abstract |
[Bayar, Banu; Akbulat, Akif] Minist Hlth Turkey, Gen Directorate Pharmaceut & Med Devices, Ankara, Turkey. |
|
dc.source |
ONCOTARGETS AND THERAPY |
|
dc.title |
Efficacy of sorafenib in advanced differentiated and medullary thyroid |
|
dc.title |
cancer: experience in a Turkish population |
|